Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about JUNS, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Oxygen at 1.5 ATA (atmospheres absolute). | Traumatic Brain Injury | Phase 1/2 · NCT01847755 | Completed |
| Trans-Resveratrol | Parkinson's Disease | Phase 2 · NCT07592767 | Recruiting |
Also used in these trials (approved or third-party drugs, not JUNS's own candidates): Pimozide, Crisaborole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
JUNS holds $1.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.9M/quarter from operations, an estimated runway of 2.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 65 · High
Factors that could cause or contribute to these differences include, but are not limited to, those identified below and those discussed in the section titled Risk Factors in this filing and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (the…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JUNS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Christer Rosen CEO and Chairman, Director · +747,783 options |
Insider | 11,078,892 | 840.25% | 2025-07-01 |
| Marshall A. Hayward Chief Scientific Officer, Director · +259,231 options |
Insider | 2,995,077 | 227.15% | 2025-06-02 |
| Claes Robert Wahlestedt 10% owner |
Insider | 2,757,353 | 209.12% | 2024-11-08 |
| Alexander Gustaf Erik Rosen Chief Administrative Officer · +341,843 options |
Insider | 617,411 | 46.83% | 2025-06-02 |
| PharmAla Biotech Holdings Inc. | 5%+ holder (13G) | 132,867 | 10.08% | 2026-09-30 |
| Alison D. Silva President and COO, Director · +1.28M options |
Insider | 112,777 | 8.55% | 2025-07-01 |
| Orca Capital AG | 5%+ holder (13G) | 102,564 | 7.78% | 2026-08-21 |
| Holger Weis Director · +100,000 options |
Insider | 96,581 | 7.32% | 2025-06-02 |
| Nicholas H. Hemmerly Director · +100,000 options |
Insider | 95,550 | 7.25% | 2025-06-02 |
| Julie B. Kampf Director · +100,000 options |
Insider | 82,875 | 6.29% | 2025-06-02 |
| Saleem Elmasri Chief Financial Officer · +627,693 options |
Insider | 66,239 | 5.02% | 2025-06-02 |
| Allison W Brady Director · +100,000 options |
Insider | 21,750 | 1.65% | 2025-01-22 |
Share count 1,318,521 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JUNS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →